Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial

The Lancet Respiratory Medicine

Volumn 5, Issue 1, 2017, Pages 22-32

  Raghu, Ganesh ^a   Brown, Kevin K ^b   Collard, Harold R ^c   Cottin, Vincent ^d   Gibson, Kevin F ^e   Kaner, Robert J ^f   Lederer, David J ^g   Martinez, Fernando J ^f   Noble, Paul W ^h   Song, Jin Woo ⁱ   Wells, Athol U ^j   Whelan, Timothy P M ^k   Wuyts, Wim ^l   Moreau, Emmanuel ^m   Patterson, Scott D ⁿ   Smith, Victoria ⁿ   Bayly, Selina ⁿ   Chien, Jason W ⁿ   Gong, Qi ⁿ   Zhang, Jenny J ⁿ   O'Riordan, Thomas G ⁿ   more..

^a UNIVERSITY OF WASHINGTON   (United States)

^b NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITÉ DE LYON   (France)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g Department of Medicine   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ University of Ulsan   (South Korea)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^l UNIVERSITY OF LEUVEN   (Belgium)

^m BIOMÉRIEUX   (France)

ⁿ Clinical Research Division   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; OXIDOREDUCTASE; PLACEBO; PROTEIN LOXL2; SIMTUZUMAB; UNCLASSIFIED DRUG; ENZYME INHIBITOR; INDOLE DERIVATIVE; LOXL2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PIRFENIDONE; PYRIDONE DERIVATIVE;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPNEA; ENZYME BLOOD LEVEL; FATIGUE; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SURVIVAL TIME; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AMINO ACID OXIDOREDUCTASES; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INDOLES; MALE; MIDDLE AGED; PYRIDONES; TREATMENT OUTCOME;

EID: 85006253698     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30421-0     Document Type: Article

References (20)

1. 1 Raghu, G, Collard, HR, Egan, JJ, et al. An official ATS/ERS/JRS/ALAT statement: IPF: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 (2011), 788–824.
2. 2 Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192 (2015), E3–19.
3. 3 King, TE Jr, Bradford, WZ, Castro-Bernardini, S, et al. A phase 3 trial of pirfenidone in patients with IPF. N Engl J Med 370 (2014), 2083–2092.
4. 4 Richeldi, L, du Bois, RM, Raghu, G, et al. Efficacy and safety of nintedanib in IPF. N Engl J Med 370 (2014), 2071–2082.
5. 5 Barry-Hamilton, V, Spangler, R, Marshall, D, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med 16 (2010), 1009–1017.
6. 6 Mehal, WZ, Iredale, J, Friedman, SL, Scraping fibrosis: expressway to the core of fibrosis. Nat Med 17 (2011), 552–553.
7. 7 Haase, VH, Hypoxia-inducible factor signaling in the development of kidney fibrosis. Fibrogenesis Tissue Repair, 5(suppl 1), 2012, S16.
8. 8 Chien, JW, Richards, TJ, Gibson, KF, et al. Serum lysyl oxidase-like 2 levels and IPF disease progression. Eur Respir J 43 (2014), 1430–1438.
9. 9 Yorke, J, Jones, PW, Swigris, JJ, Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax 65 (2010), 921–926.
10. 10 Rodriguez, HM, Vaysberg, M, Mikels, A, et al. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J Biol Chem 285 (2010), 20964–20974.
11. 11 Moore, B, Lawson, WE, Oury, TD, Sisson, TH, Raghavendran, K, Hogaboam, CM, Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol 49 (2013), 167–179.
12. 12 Moeller, A, Ask, K, Warburton, D, Gauldie, J, Kolb, M, The bleomycin animal model: a useful tool to investigate treatment options for IPF?. Int J Biochem Cell Biol 40 (2008), 362–382.
13. 13 Nishioka, T, Eustace, A, West, C, Lysyl oxidase: from basic science to future cancer treatment. Cell Struct Funct 37 (2012), 75–80.
14. 14 Olsen, KC, Sapinoro, RE, Kottmann, RM, et al. Transglutaminase 2 and its role in pulmonary fibrosis. Am J Respir Crit Care Med 184 (2011), 699–707.
15. 15 Philp C, Clements D, Jenkins G, Johnson S. Fibroblasts from patients with IPF generate structurally different extra-cellular matrix which enhances fibroblast proliferation dependent upon matrix cross linking. 18th International Colloquium on Lung and Airway Fibrosis. Mont-Tremblant, Quebec, Canada, 2014.
16. 16 Lugassy, J, Zaffryar-Eilot, S, Soueid, S, et al. The enzymatic activity of lysyl oxidase-like-2 (LOXL2) is not required for LOXL2-induced inhibition of keratinocyte differentiation. J Biol Chem 287 (2012), 3541–3549.
17. 17 Iftikhar, M, Hurtado, P, Bais, MV, et al. Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation. J Biol Chem 286 (2011), 909–918.
18. 18 Karimi-Shah, BA, Chowdhury, BA, Forced vital capacity in IPF—FDA review of pirfenidone and nintedanib. N Engl J Med 372 (2015), 1189–1191.
19. 19 ESBRIET (pirfenidone) capsules, for oral use. Full Prescribing Information, 2016, Genentech USA, Inc., South San Francisco, CA, USA.
20. 20 OFEV (nintedanib) capsules, for oral use full prescribing information, 2014, Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT.